Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.04 by 62.16 percent. This is a 300 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $85.807 million which beat the analyst consensus estimate of $82.340 million by 4.21 percent. This is a 42.78 percent increase over sales of $60.099 million the same period last year.